Core Viewpoint - The Hong Kong stock market is currently at a historical median valuation, presenting a high cost-performance ratio compared to major global markets, and may see increased allocation opportunities due to factors like U.S. interest rate cuts [3][4]. Market Performance - Recent performance of key indices includes: - Hang Seng Index: +5.12% - Hang Seng Biotechnology Index: +10.08% - Hang Seng Technology Index: +12.11% - Hong Kong Stock Connect Mainland: -3.73% - Financial Index: +0.79% - Dividend Index: +5.12% [3][17]. Macro Environment - The macroeconomic environment is favorable for Hong Kong stocks, with interest rate cuts improving liquidity and policy optimizations enhancing the institutional framework [4][5]. Policy Support - Continuous policy support includes: - Central State-Owned Assets Supervision and Administration Commission (SASAC) incorporating state-owned enterprise (SOE) market value management into performance assessments, emphasizing high dividend asset allocation [5]. - Hong Kong government initiatives to assist tech companies in financing and optimizing listing rules, which enhance market efficiency and international competitiveness [5][9]. Investment Strategy - In the current market, sectors such as financials and dividend stocks are seen as safe havens due to their high dividend yields and defensive characteristics, while innovative pharmaceuticals and technology sectors are expected to show high growth potential due to policy support and industrial upgrades [7][8]. Index Comparisons - Key indices and their focus areas include: - Central State-Owned Enterprises Dividend Index: Focuses on stable dividend-paying SOEs [13]. - Financial Index: Concentrates on banks and non-bank financial institutions [14]. - Hang Seng Technology Index: Covers a diverse range of tech sectors including internet and semiconductors [15]. - Hang Seng Biotechnology Index: Targets innovative pharmaceuticals and the entire biotech supply chain [16]. Global Technology Landscape - The global technology race has entered a new phase characterized by increased capital expenditure from major U.S. and Chinese firms, driving advancements in AI infrastructure, semiconductors, and large models, indicating a golden period for the tech industry [10].

Core Viewpoint - The Chinese innovative pharmaceutical sector is experiencing significant growth, with companies transitioning from generic to innovative drug development, and is expected to continue as a key investment theme in the medium to long term [1][2]. Group 1: Market Performance - The three major A-share indices rose collectively in early trading, with the Shanghai Composite Index up 0.1% to 3916.1 points, the Shenzhen Component Index up 0.15%, and the ChiNext Index up 0.69% [1]. - The total trading volume in the Shanghai and Shenzhen markets reached 12,229 billion yuan, a decrease of 576 billion yuan from the previous day, with over 1,200 stocks rising [1]. Group 2: Innovative Drug Sector - The innovative drug concept stocks strengthened again, with various Hong Kong innovative drug ETFs rising over 2% [1]. - The upcoming European Society for Medical Oncology (ESMO) conference in October 2025 is anticipated to showcase new data from innovative drug companies, including domestic firms like Kangfang Biotech and Hengrui Medicine [1]. Group 3: Industry Insights - The Chinese pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs significantly opening new growth avenues for companies [1]. - Major traditional pharmaceutical companies like Hengrui Medicine and Hansoh Pharmaceutical have successfully transformed into innovative firms, while emerging companies are rapidly gaining global recognition [1]. - The aging population is driving demand for chronic disease treatments, contributing to the growth of the silver economy [1]. - The healthcare payment system is steadily growing, with the National Healthcare Security Administration promoting the development of commercial insurance [1]. - The rise of AI is expected to introduce new growth logic in the pharmaceutical industry, with a positive outlook for innovative drugs and medical devices [1]. Group 4: Investment Recommendations - The innovative drug sector is projected to maintain high revenue growth and reduce losses, with Q3 expected to continue this trend [2]. - Investment opportunities are suggested in sectors with improving performance, such as CXO, upstream scientific reagents, and medical devices [2].

Market Overview - The Hang Seng Index is expected to hold at 25,000 points, with a forecasted P/E ratio of 12 times over the next 12 months, amid concerns over U.S.-China trade tensions and weak consumer spending in China [2] - The U.S. Federal Reserve's recent hawkish stance on interest rate cuts has led to reduced expectations for future rate reductions, with a potential cut of only one time in 2026, contrary to market expectations of three cuts [3] Economic Indicators - In September, new loans in China reached 1.29 trillion yuan, more than double the previous month, driven by consumer loan incentives [9] - The core inflation rate in China was reported at 1% for the first time in over a year and a half, indicating a slight recovery in consumer prices, although overall CPI fell by 0.3% due to declining food prices [10] Corporate Developments - China Tower (0788) and Fuyao Glass (3606) are in focus for their upcoming earnings reports [7] - SenseTime (0020) has entered a strategic partnership with Cambricon (688256.SH) to enhance AI infrastructure and services [11] - Xiaomi (1810) has launched its Double 11 promotional campaign, offering discounts totaling 2 billion yuan [11] - Nine Dragons Paper (9922) reported a narrowing decline in same-store sales, reflecting successful operational adjustments [11] Sector Performance - The insurance sector is expected to benefit from strong investment returns in Q3, driven by robust A-share market performance [7] - AI-related stocks are gaining traction as China accelerates the application of digital technologies [7] Trade Relations - The U.S. and China are in a trade war, with President Trump indicating plans to impose additional tariffs on Chinese goods if no agreement is reached [9] - The U.S. Treasury Secretary suggested extending the 90-day tariff suspension period to resolve key mineral conflicts [9]

Core Viewpoint - The Hong Kong Stock Connect innovative drug sector is showing strong performance, with the Hong Kong Stock Connect Innovative Drug ETF (520880) experiencing significant trading activity and price increases, indicating a bullish sentiment in the market [1][4]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) surged by nearly 4% in early trading, surpassing its 5-day moving average, with trading volume exceeding 400 million yuan, surpassing the previous day's total [1]. - The ETF covers 37 innovative drug research companies, with 36 stocks showing gains, including notable increases from companies like BeiGene and China Biologic Products [4]. - The index tracked by the ETF has shown a year-to-date increase of 108.14%, outperforming other innovative drug indices [8]. Group 2: Key Companies and Their Performance - Major companies within the ETF include: - BeiGene (6160) with a weight of 10.46%, current price at 191.60, and a 2.13% increase [2]. - China Biologic Products (1177) with a weight of 10.01%, current price at 7.66, and a 2.00% increase [2]. - Innovent Biologics (1801) with a weight of 9.20%, current price at 88.35, and a 3.21% increase [2]. - Other notable performers include CanSino Biologics and 3SBio, with increases of over 6% and 7% respectively [4]. Group 3: Upcoming Events and Opportunities - The European Society for Medical Oncology (ESMO) annual meeting is scheduled from October 17 to 21 in Berlin, which is expected to be a significant platform for domestic pharmaceutical companies to showcase their achievements and explore new business development opportunities [2]. - Recent business development transactions, such as the $100 million upfront payment by Innovent Biologics, indicate a robust pipeline for potential deals in the coming months, particularly in the traditional peak season for such transactions [3]. Group 4: Policy and Economic Environment - Domestic policy adjustments in the medical insurance directory are expected to support genuine innovation, providing a stable outlook for commercialization [3]. - The resumption of the Federal Reserve's interest rate cut cycle is anticipated to benefit the Hong Kong Stock Connect innovative drug sector through improved valuation and financing conditions [3].

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) has shown strong performance, with significant inflows and a focus on the upcoming ESMO conference, highlighting investment opportunities in Chinese innovative pharmaceuticals [1][2] Group 1: ETF Performance - As of October 16, 2025, the Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) increased by 2.63%, with a turnover of 7.19% and a transaction volume of 52.87 million yuan [1] - The ETF's latest scale reached 709 million yuan, with shares totaling 784 million, both hitting record highs since inception [1] - The ETF has seen continuous net inflows over the past nine days, totaling 399 million yuan [1] Group 2: Market Trends and Opportunities - The 2025 European Society for Medical Oncology (ESMO) conference, scheduled for October 17-21 in Berlin, will focus on breakthrough therapies in lung and breast cancer, showcasing the R&D capabilities of Chinese pharmaceutical companies [1] - Huafu Securities believes that the innovative drug sector in China is entering a phase where quantitative changes will lead to qualitative improvements, with a positive outlook for the next 5-10 years driven by business development (BD) overseas, continuous data catalysts, and new product sales [1][2] - CICC highlights that domestic innovative drugs are transitioning from following trends to FIC/BIC innovations, marking a qualitative upgrade in the industry [2] Group 3: Index and Major Stocks - The Hong Kong Stock Connect Innovative Drug ETF closely tracks the National Index of Hong Kong Stock Connect Innovative Drugs, which reflects the performance characteristics of listed companies in the innovative drug sector [2] - The top ten weighted stocks in the index include Baijiazhenshou, Kangfang Biotech, Xinda Biopharma, China Biopharmaceutical, Shiyao Group, Sanofi, Hansoh Pharmaceutical, Kelun-Botai Biotech, Zai Lab, and Rongchang Biotech [2]

Group 1 - The Hong Kong innovative drug sector has rebounded strongly for the second consecutive day, with notable stock increases for companies such as 3SBio (+7.76%), InnoCare Pharma (+6.88%), and CanSino Biologics (+6.72%) [1] - The upcoming European Society for Medical Oncology (ESMO) annual meeting from October 17 to 21 in Berlin is expected to be a catalyst for domestic innovative drug companies, including CanSino Biologics, Kelun-Biotech, and others [1] - The market is also focused on the third-quarter earnings reports, with a significant trend of new product launches and accelerating revenue for traditional pharmaceutical companies like Hengrui Medicine and BeiGene [1] Group 2 - The Hang Seng Medical ETF (159892) has seen a net inflow of 420 million yuan over the past four days, indicating strong investor interest [1] - The innovative drug industry is expected to maintain its core direction of "innovation + internationalization," with ongoing policy support and enhanced global competitiveness [1] - The Hong Kong Medical ETF (520510) has a leading concentration of CXO stocks, including WuXi AppTec, MicroPort Medical, and JD Health, reflecting a strong focus on AI in healthcare [2]

Group 1 - The Hong Kong innovative pharmaceutical stocks showed strong performance in early trading, with companies like Sangfor Pharma rising over 8%, and Kangfang Biotech increasing by over 6% [1] - Several Hong Kong innovative pharmaceutical ETFs also experienced gains of over 3%, influenced by the rise of heavyweight stocks [1] Group 2 - A report from a brokerage indicates that the Chinese innovative pharmaceutical industry has formed a pyramid structure led by top enterprises, supported by a large number of quality companies, demonstrating strong sustainability [2] - The underlying logic of this cycle is that China's innovative drugs in development possess global competitiveness, with the realization of value shifting from domestic sales to international data and transaction monetization [2] - The commercialization space is expanding, leading to a healthier and more mature ecosystem, gradually transitioning into a dual-driven phase of products and business models [2]

高开低走后全天震荡下行，截至收盘恒生指数下跌1.73%。恒生科技跌幅居前，工商、国指ESG、内房 地、内石油等紧随其后；内银行逆势上涨，恒生公用紧随其后。 恒生科技低开低走后全天震荡下行，截至收盘下跌3.62%，其中华虹半导体大跌13.08%，金蝶国际和中 芯国际均下跌8.48%，哔哩哔哩、商汤等多股跌幅均在7%上方。 恒生工商也弱势明显，截至收盘下跌2.7%。其中石药集团大跌7.08%，快手下跌6.77%，紫金矿业下跌 6.54%，银河娱乐、中国生物制药、百度集团、翰森制药等多股跌幅均在5%上方。 内银行低开高走后震荡上行，随后全天维持在高位盘整，截至收盘上涨1.89%。其中重庆农村商业银行 大涨6.14%，招商银行上涨4.7%，中信银行、建设银行等多股涨幅均在2%上方。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ ...

Major Events - Meili Tianyuan Medical Health (02373) acquires 100% of Shanghai Siyuanli Industrial for 1.25 billion yuan, aiming to capture the high-end beauty market in major cities [1] - Jinhai Medical Technology (02225) is actively preparing to participate in the 8th China International Import Expo [1] - China Biopharmaceutical (01177) has its selective MEK1/2 inhibitor TQ-B3234 included in the breakthrough therapy designation program [1] - Beijing Jiakesi plans to sell 90% of Jiakexi Health through capital increase and equity transfer agreements [1] - Green Power Environmental (01330) intends to invest in establishing a joint venture in Hong Kong to expand overseas environmental business [1] - Zhonghui Biotechnology (02627) applies for full circulation of H-shares [1] Operating Performance - Legend Holdings (03396) reports that its subsidiary, Legend New Science (003022.SZ), achieved a net profit attributable to shareholders of 232 million yuan in the first three quarters, an increase of 30.32% [1] - Mongol Mining (00975) reports total raw coal production of 3.6043 million tons from UHG and BN mines in the third quarter [1] - China Resources Power (00836) reports cumulative electricity sales of 161 million megawatt-hours from its subsidiary power plants in the first nine months, a year-on-year increase of 4.2% [1] - China Coal Energy (01898) reports coal sales of 19.66 million tons in September, a year-on-year decrease of 20.1% [1] - Air China (00753) reports a 1.2% year-on-year increase in passenger capacity input and a 5.6% year-on-year increase in passenger turnover in September [1]

Core Viewpoint - Fudan Zhangjiang's application for the drug Ocaliva (Obeticholic Acid) has been rejected by the National Medical Products Administration due to safety concerns and lack of sufficient evidence to support its approval as a generic drug [1][4]. Group 1: Company Updates - Fudan Zhangjiang's subsidiary, Taizhou Fudan Zhangjiang Pharmaceutical Co., received a notification of non-approval for its drug application for Obeticholic Acid, which is intended for treating primary biliary cholangitis (PBC) [1]. - The company has invested approximately 125 million yuan in the development of Obeticholic Acid [1]. - The rejection of the drug application is not expected to have a significant impact on the company's current financial status [1]. Group 2: Industry Context - Obeticholic Acid, originally developed by Intercept Pharmaceuticals, was first approved by the FDA in May 2016 and subsequently received conditional approval in Europe [2]. - The global sales of Obeticholic Acid showed steady growth from 2016 to 2021, reaching approximately $363 million in 2021 before stabilizing around $300 million in subsequent years [2]. - Safety concerns regarding Obeticholic Acid have led to multiple warnings and restrictions, including its classification under a "black box warning" by the FDA due to reports of severe liver damage and increased risk of liver transplant and death [3]. - The European Medicines Agency recommended the withdrawal of Obeticholic Acid's marketing authorization in 2023, and Intercept Pharmaceuticals voluntarily withdrew the drug from the U.S. market in September 2023 [3]. - There are currently no approved Obeticholic Acid products in China, and the safety risks associated with the original drug have created uncertainty for domestic generic drug prospects [4]. - Other domestic companies, including Hengrui Medicine and Zai Lab, are also facing setbacks in their applications for Obeticholic Acid generics, with some projects being halted after significant investments [5].